论文信息 - Phase I Study of IPH4102, Anti‐KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T‐Cell Lymphomas (CTCL): Dose‐escalation Safety, Biomarker and Clinical Activity Results - 字舞流文

Phase I Study of IPH4102, Anti‐KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T‐Cell Lymphomas (CTCL): Dose‐escalation Safety, Biomarker and Clinical Activity Results

S. Whittaker | M. Khodadoust | M. Bagot | M. Duvic | M. Battistella | A. Bensussan | C. Bonnafous | H. Sicard | A. Marie-Cardine | C. Paturel | N. Thonnart | M. Vermeer | A. Widemann | C. Bonin | K. Pilz | C. Ram-Wolff | P. Porcu | Y. Kim | S. Mathieu | W. Basem | C. Paiva